Cargando…

Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection

The efficacy and the long-term protection of a recombinant feline leukemia virus (FeLV) vaccine were determined in 30 specified pathogen free cats for over 3 years. At the same time, in order to specify the effects of feline immunodeficiency virus (FIV) on the immune system, one half of the cats (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann-Lehmann, R., Holznagel, E., Aubert, A., Ossent, P., Reinacher, M., Lutz, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119625/
https://www.ncbi.nlm.nih.gov/pubmed/7618252
http://dx.doi.org/10.1016/0165-2427(94)07012-V
_version_ 1783514802823364608
author Hofmann-Lehmann, R.
Holznagel, E.
Aubert, A.
Ossent, P.
Reinacher, M.
Lutz, H.
author_facet Hofmann-Lehmann, R.
Holznagel, E.
Aubert, A.
Ossent, P.
Reinacher, M.
Lutz, H.
author_sort Hofmann-Lehmann, R.
collection PubMed
description The efficacy and the long-term protection of a recombinant feline leukemia virus (FeLV) vaccine were determined in 30 specified pathogen free cats for over 3 years. At the same time, in order to specify the effects of feline immunodeficiency virus (FIV) on the immune system, one half of the cats (n = 15) were previously infected with the Swiss isolate FIV Zurich 2. The second half of the animals (n = 15) served as non-infected controls. Eighteen (nine FIV-negative, nine FIV-positive) vaccinated and 12 (six FIV-negative, six FIV-positive) non-vaccinated cats were intraperitoneally challenged with FeLV A. Seventeen of 18 vaccinated cats were protected against persistent viremia, while ten of 12 non-vaccinated controls became infected. An increase of antibodies against FeLV SU was found in all protected cats after the challenge exposure. No difference in vaccine efficacy was found between FIV-negative and FIV-positive animals. The whole group of cats was observed for over 3 years. There were no further vaccinations during this period. CD4(+) and CD8(+) cell subsets, clinical outcome and time of survival of the cats were recorded. FIV-negative and FIV-positive animals were kept in two different rooms. However, FeLV-negative and FeLV viremic cats were housed together in both rooms in order to imitate a natural FeLV exposure situation. Anti-recombinant FeLV SU antibodies were measured by enzyme-linked immunosorbent assay. Although a continuous decline of antibodies was found in FeLV vaccinated cats, they remained protected against constant FeLV challenge for over 3 years. FIV infection had a stronger effect on the depression of the CD4(+):CD8(+) ratio than FeLV infection. Within the group of FIV-positive cats, the FeLV-vaccinated animals had significantly better survival rates as well as better clinical and laboratory parameters. FIV- and FeLV-coinfected cats showed the lowest CD4(+):CD8(+) ratio, mainly caused by decreased CD4(+) lymphocyte counts. CD8(+) lymphocytes with strong fluorescence (CD8(high)) disappeared and cells with weak fluorescence (CD8(low)) appeared instead. Prevention of coinfection by immunizing FIV-positive cats against FeLV infection improved the clinical outcome and prolonged the cat's life expectancy.
format Online
Article
Text
id pubmed-7119625
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71196252020-04-08 Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection Hofmann-Lehmann, R. Holznagel, E. Aubert, A. Ossent, P. Reinacher, M. Lutz, H. Vet Immunol Immunopathol Article The efficacy and the long-term protection of a recombinant feline leukemia virus (FeLV) vaccine were determined in 30 specified pathogen free cats for over 3 years. At the same time, in order to specify the effects of feline immunodeficiency virus (FIV) on the immune system, one half of the cats (n = 15) were previously infected with the Swiss isolate FIV Zurich 2. The second half of the animals (n = 15) served as non-infected controls. Eighteen (nine FIV-negative, nine FIV-positive) vaccinated and 12 (six FIV-negative, six FIV-positive) non-vaccinated cats were intraperitoneally challenged with FeLV A. Seventeen of 18 vaccinated cats were protected against persistent viremia, while ten of 12 non-vaccinated controls became infected. An increase of antibodies against FeLV SU was found in all protected cats after the challenge exposure. No difference in vaccine efficacy was found between FIV-negative and FIV-positive animals. The whole group of cats was observed for over 3 years. There were no further vaccinations during this period. CD4(+) and CD8(+) cell subsets, clinical outcome and time of survival of the cats were recorded. FIV-negative and FIV-positive animals were kept in two different rooms. However, FeLV-negative and FeLV viremic cats were housed together in both rooms in order to imitate a natural FeLV exposure situation. Anti-recombinant FeLV SU antibodies were measured by enzyme-linked immunosorbent assay. Although a continuous decline of antibodies was found in FeLV vaccinated cats, they remained protected against constant FeLV challenge for over 3 years. FIV infection had a stronger effect on the depression of the CD4(+):CD8(+) ratio than FeLV infection. Within the group of FIV-positive cats, the FeLV-vaccinated animals had significantly better survival rates as well as better clinical and laboratory parameters. FIV- and FeLV-coinfected cats showed the lowest CD4(+):CD8(+) ratio, mainly caused by decreased CD4(+) lymphocyte counts. CD8(+) lymphocytes with strong fluorescence (CD8(high)) disappeared and cells with weak fluorescence (CD8(low)) appeared instead. Prevention of coinfection by immunizing FIV-positive cats against FeLV infection improved the clinical outcome and prolonged the cat's life expectancy. Published by Elsevier B.V. 1995-05 2000-03-16 /pmc/articles/PMC7119625/ /pubmed/7618252 http://dx.doi.org/10.1016/0165-2427(94)07012-V Text en Copyright © 1995 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hofmann-Lehmann, R.
Holznagel, E.
Aubert, A.
Ossent, P.
Reinacher, M.
Lutz, H.
Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
title Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
title_full Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
title_fullStr Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
title_full_unstemmed Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
title_short Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
title_sort recombinant felv vaccine: long-term protection and effect on course and outcome of fiv infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119625/
https://www.ncbi.nlm.nih.gov/pubmed/7618252
http://dx.doi.org/10.1016/0165-2427(94)07012-V
work_keys_str_mv AT hofmannlehmannr recombinantfelvvaccinelongtermprotectionandeffectoncourseandoutcomeoffivinfection
AT holznagele recombinantfelvvaccinelongtermprotectionandeffectoncourseandoutcomeoffivinfection
AT auberta recombinantfelvvaccinelongtermprotectionandeffectoncourseandoutcomeoffivinfection
AT ossentp recombinantfelvvaccinelongtermprotectionandeffectoncourseandoutcomeoffivinfection
AT reinacherm recombinantfelvvaccinelongtermprotectionandeffectoncourseandoutcomeoffivinfection
AT lutzh recombinantfelvvaccinelongtermprotectionandeffectoncourseandoutcomeoffivinfection